English 
Deutsch 
The strong Swissfillon AG team celebrated the successful completion of the FDA inspection with a team event on April 26, 2019. The team members gathered at the Visp railway station at 09:00 o’clock local time on that Friday. Even the rainy weather could not stop them from taking the bus to Ausserberg to face their
Visp, May 9th 2019 – Swissfillon AG ,an agile fill & finish contract manufacturing organization (CMO) for complex pharmaceutical and biopharmaceutical products, announces todaysuccessful facility inspection of its GMP manufacturing site, located in Visp. The Swissfillon production site in Visp was assessed by the USFDA (US Food and Drug Administration) between April 15 and 24, 2019.
Swissfillon AG in Visp has faced the scrutiny of the FDA – Food and Drug Administration – between April 15 and 24, 2019. After intensive seven days in which the Swissfillon AG team faced the questions and challenges of the inspectors, the following emerged: The FDA inspectors have given their okay, so that Swissfillon AG
Between 15 and 19 April 2019, Swissfillon AG in Visp will face the scrutiny of the FDA – Food and Drug Administration. The inspection authority is the Food and Drug Administration of the USA. It has set itself the task of protecting public health in the United States and, in this context, monitors the safety
